Twist Bioscience Posts Fourth-Quarter Loss
The South San Francisco synthetic DNA maker reported a wider loss than last year even as quarterly revenue topped analyst expectations.
Updated on Nov. 12, 2026 in Biotech

Twist Bioscience reported a fiscal fourth-quarter net loss of $20.6 million, or 32 cents per share, while revenue reached $126.6 million. The result beat the $123.4 million that three analysts surveyed by Zacks had expected.
Why it matters
The quarter shows revenue growth outpacing expectations for a company that makes synthetic DNA for biotechnology customers, though losses remain significant. Investors are watching whether the company can narrow losses as sales climb.
Fourth-quarter revenue of $126.6 million beat the $123.4 million analyst estimate from Zacks, while the company posted a loss of 32 cents per share. The fiscal-year net loss was $130.2 million, or $2.08 per share, on revenue of $459.4 million.
The players
Twist Bioscience Corp.
A South San Francisco company that manufactures synthetic DNA and sells it to biotechnology and life-science customers.
The details
Twist Bioscience, based in South San Francisco, California, makes synthetic DNA used across the biotechnology industry. The company reported its fiscal fourth-quarter results on Thursday, November 12, 2026, and also issued revenue guidance for the coming periods.
Timeline
Thursday, November 12, 2026: Twist Bioscience reports fiscal fourth-quarter results.
December 2026: Quarter for which the company expects revenue of $130 million to $132 million.
Season Trajectory
Against the $123.4 million Zacks consensus, Twist Bioscience's $126.6 million quarter represents a revenue beat relative to what three analysts had projected. The company's guidance of $550 million to $560 million for the full year frames whether that beat signals a sustained acceleration.
For readers following the company's products, Twist Bioscience's revenue guidance indicates expected sales of $130 million to $132 million for the quarter ending in December. The results matter mainly to investors and researchers who rely on synthetic DNA supply from the company.
The takeaway
Revenue growth that beats analyst forecasts can matter even while losses persist, so readers tracking the sector should watch whether future quarters show losses narrowing alongside rising sales.
Further reading
For more on the sector, see Biotech coverage across California.










